Bivalirudin

Evidence Level: N/A

Predicted Indications: 0

---

Table of Contents

1. Bivalirudin
   1. Pharmacist Assessment Report
   2. Bivalirudin: Known uses and market status in Australia
   3. Summary
   4. Quick overview
   5. Known uses recorded for this drug
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. Australia Market Information
   7. Safety Considerations
   8. Disclaimer

---

Pharmacist Assessment Report

Bivalirudin: Known uses and market status in Australia

Summary

The TxGNN model has no candidate with a score of 0.99 or higher for Bivalirudin, so there is currently no new predicted indication. The drug’s recorded uses are listed below. No known uses are recorded for this drug in the available data.

Quick overview

Item	Content
New predicted indications	None (no model candidate scored 0.99 or higher)
Known uses recorded for this drug	0
Evidence level	Not applicable
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)

Known uses recorded for this drug

Approved (supported by a licence or label)

Indication	Source
none	none

Related to an approved indication (same disease category)

Indication	Approved category
none	none

Relations recorded in the knowledge graph (no approval found)

Indication
none

Australia Market Information

Licence	Product	Dosage form	Status
8844L	BIVALIRUDIN ARX	Powder for I.V. injection 250 mg (as tri	Valid

Safety Considerations

• Knowledge-graph contraindication signal: The TxGNN knowledge graph records a contraindication with intracranial haemorrhage. This comes from graph data, not from label text.
• Drug Interactions: The interaction query returned 100 entries. The first 20 reviewed include several rated Major:
  • Anticoagulants and thrombolytics: fondaparinux, alteplase
  • Antiplatelet agent: abciximab (Moderate)
  • Targeted anticancer agents: acalabrutinib, trastuzumab emtansine
  • Other Major entries: deferasirox, ibritumomab tiuxetan, tositumomab (including I-131)
  • Moderate examples: NSAIDs (ketorolac, ibuprofen, topical diclofenac), fluvoxamine, sugammadex, fenfluramine, dexfenfluramine, sibutramine, radioiodine (I-123, I-131)

  Many of these interactions raise bleeding risk, which is directly relevant to any bleeding-disorder indication.

Please refer to the TGA-approved Product Information (PI) for full warnings and contraindications, as these were not available in the data compiled for this report.

---

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---